BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 18524797)

  • 21. [The place of insulin-like growth factor I in the diagnosis of acromegaly].
    Dohán O; Góth M; Szabolcs I; Kovács L; Kovács Z; Szilágyi G
    Orv Hetil; 1993 Oct; 134(42):2301-3. PubMed ID: 8233444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.
    Ayuk J; Clayton RN; Holder G; Sheppard MC; Stewart PM; Bates AS
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1613-7. PubMed ID: 15070920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.
    Bianchi A; Giustina A; Cimino V; Pola R; Angelini F; Pontecorvi A; De Marinis L
    J Clin Endocrinol Metab; 2009 Jun; 94(6):2015-22. PubMed ID: 19336510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A nationwide survey of mortality in acromegaly.
    Kauppinen-Mäkelin R; Sane T; Reunanen A; Välimäki MJ; Niskanen L; Markkanen H; Löyttyniemi E; Ebeling T; Jaatinen P; Laine H; Nuutila P; Salmela P; Salmi J; Stenman UH; Viikari J; Voutilainen E
    J Clin Endocrinol Metab; 2005 Jul; 90(7):4081-6. PubMed ID: 15886256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of serum growth hormone (GH) and insulin-like growth factor I in active acromegaly with minimal elevation of serum GH.
    Daughaday WH; Starkey RH; Saltman S; Gavin JR; Mills-Dunlap B; Heath-Monnig E
    J Clin Endocrinol Metab; 1987 Oct; 65(4):617-23. PubMed ID: 3654910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peroxisome proliferator activated receptor gamma expression is reduced in the colonic mucosa of acromegalic patients.
    Bogazzi F; Ultimieri F; Raggi F; Costa A; Gasperi M; Cecconi E; Mosca F; Bartalena L; Martino E
    J Clin Endocrinol Metab; 2002 May; 87(5):2403-6. PubMed ID: 11994396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on "safe" GH cut-off values?
    Kohler S; Tschopp O; Sze L; Neidert M; Bernays RL; Spanaus KS; Wiesli P; Schmid C
    Gen Comp Endocrinol; 2013 Jul; 188():282-7. PubMed ID: 23648743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy).
    Colao A; Vandeva S; Pivonello R; Grasso LF; Nachev E; Auriemma RS; Kalinov K; Zacharieva S
    Eur J Endocrinol; 2014 Aug; 171(2):263-73. PubMed ID: 24878680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.
    Colao A; Pivonello R; Cavallo LM; Gaccione M; Auriemma RS; Esposito F; Cappabianca P; Lombardi G
    Clin Endocrinol (Oxf); 2006 Aug; 65(2):250-6. PubMed ID: 16886969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas.
    Minniti G; Jaffrain-Rea ML; Osti M; Esposito V; Santoro A; Solda F; Gargiulo P; Tamburrano G; Enrici RM
    Clin Endocrinol (Oxf); 2005 Feb; 62(2):210-6. PubMed ID: 15670198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly.
    Espinosa-de-los-Monteros AL; Mercado M; Sosa E; Lizama O; Guinto G; Lopez-Felix B; Garcia O; Hernández I; Ovalle A; Mendoza V
    J Neurosurg; 2002 Aug; 97(2):287-92. PubMed ID: 12186455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
    Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biochemical evidence supporting the Cortina criteria.
    von Werder K
    J Endocrinol Invest; 2005; 28(11 Suppl International):81-3. PubMed ID: 16625853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
    Elias PC; Lugao HB; Pereira MC; Machado HR; Castro Md; Moreira AC
    Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acromegaly and serum insulin-like growth factor I.
    Thorner MO
    Horm Res; 2004; 62 Suppl 1():34-6. PubMed ID: 15761230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biochemical evidence in favor of revising Cortina criteria.
    Webb SM; Sucunza N; Barahona MJ
    J Endocrinol Invest; 2005; 28(11 Suppl International):84-6. PubMed ID: 16625854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ghrelin test for the assessment of GH status in successfully treated patients with acromegaly.
    Pekic S; Doknic M; Miljic D; Joksimovic M; Glodic J; Djurovic M; Dieguez C; Casanueva F; Popovic V
    Eur J Endocrinol; 2006 May; 154(5):659-66. PubMed ID: 16645012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly.
    Jenkins D; O'Brien I; Johnson A; Shakespear R; Sheppard MC; Stewart PM
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):517-22. PubMed ID: 8548933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two hour mean GH is not superior to basal GH for the follow-up of acromegalic patients treated with Octreotide LAR.
    Taboada GF; Correa LL; de Oliveira Machado E; van Haute FR; Casini AF; Balarini GA; Neto LV; Calixto L; Calixto C; Gadelha MR
    Growth Horm IGF Res; 2007 Feb; 17(1):77-81. PubMed ID: 17314058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS; Musolino NR; Salgado LR; Bronstein MD
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.